Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].
in vivo
Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1].
Animal Model:
Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1]
Dosage:
3 mg/kg
Administration:
Intravenous injection; 3 mg/kg weekly for 4 weeks
Result:
Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
References
[1] Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184. DOI:10.1016/j.canlet.2020.07.034
